Quoin Pharmaceuticals (STU:2EB0) Other Current Payables: €0.52 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2EB0 Quoin Pharmaceuticals Ltd STU:2EB0
19 GF Score
Price €215.04
! 1 Warning Sign
View Full Analysis

What is Quoin Pharmaceuticals Other Current Payables?

Quoin Pharmaceuticals STU:2EB0 19 Other Current Payables is €0.52 Mil as of Mar. 2026. GuruFocus rates STU:2EB0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Quoin Pharmaceuticals's Other Current Payables for the quarter that ended in Mar. 2026 was €0.52 Mil.

Quoin Pharmaceuticals's quarterly Other Current Payables increased from Sep. 2025 (€0.51 Mil) to Dec. 2025 (€0.51 Mil) and increased from Dec. 2025 (€0.51 Mil) to Mar. 2026 (€0.52 Mil).

Quoin Pharmaceuticals's annual Other Current Payables increased from Dec. 2023 (€0.55 Mil) to Dec. 2024 (€0.57 Mil) but then declined from Dec. 2024 (€0.57 Mil) to Dec. 2025 (€0.51 Mil).

Quoin Pharmaceuticals Other Current Payables Related Terms

Quoin Pharmaceuticals Other Current Payables Historical Data

* Premium members only.

The historical data trend for Quoin Pharmaceuticals's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quoin Pharmaceuticals Other Current Payables Chart

Quoin Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 0.53 0.57 0.55 0.57 0.51

Quoin Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.52 0.51 0.51 0.52
STU:2EB0
19GF Score
Quoin Pharmaceuticals Ltd STU:2EB0
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quoin Pharmaceuticals Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.52 Mil mean?
Quoin Pharmaceuticals (STU:2EB0) has a Other Current Payables of €0.52 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Quoin Pharmaceuticals and its competitors.
Is Quoin Pharmaceuticals' Other Current Payables too high?
Quoin Pharmaceuticals' current Other Current Payables is €0.52 Mil. Overall, Quoin Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Quoin Pharmaceuticals' Other Current Payables compare to RVPH and AIM?
Quoin Pharmaceuticals' Other Current Payables of €0.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Quoin Pharmaceuticals and its competitors. Quoin Pharmaceuticals's current Other Current Payables is €0.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quoin Pharmaceuticals stock overvalued right now?
Quoin Pharmaceuticals (STU:2EB0) has a current Other Current Payables of €0.52 Mil. The current Other Current Payables is €0.52 Mil. Quoin Pharmaceuticals' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Quoin Pharmaceuticals (STU:2EB0), the current Other Current Payables is €0.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quoin Pharmaceuticals Business Description

Other Exchanges QNRX:USA
Address 42127 Pleasant Forest Court, Ashburn, VA, USA, 20148-7349
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
19GF Score

Get the complete analysis for STU:2EB0

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€215.04
Price